E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Recessive Dystrophic Epidermolysis Bullosa (RDEB) due to mutation(s) in exon 73 of the COL7A1 gene |
|
E.1.1.1 | Medical condition in easily understood language |
RDEB due to mutation(s) in exon 73 of the COL7A1 gene |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014989 |
E.1.2 | Term | Epidermolysis bullosa |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To evaluate safety and tolerability following topical administration of QR-313 to the target wound area (TWA) - To assess the effect of QR-313 on the exclusion (skipping) of exon 73 in COL7A1 mRNA
|
|
E.2.2 | Secondary objectives of the trial |
- To assess the preliminary efficacy on wound healing and skin strength - To assess systemic exposure after topical administration of QR-313 to the Target Wound Area (TWA) - To assess the effect of QR-313 on the presence of collagen type VII protein and anchoring fibrils
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female, ≥ 6 years of age at Screening with a clinical diagnosis of RDEB with confirmation of at least one of the alleles of the COL7A1 gene containing one or more pathogenic mutations in exon 73. 2. Have at least one TWA of 10 x 10 cm that shows dynamic wound healing, no signs of local infection and in which a wound can be selected with the following criteria: a. a surface area ranging from 5 to 60 cm2 b. open wound that has healing potential c. exposed sub-epidermal tissue to allow absorption of the IMP d. no suspicion of current squamous cell carcinoma (SCC) upon visual inspection
|
|
E.4 | Principal exclusion criteria |
1. Pregnant or breast-feeding female 2. Hemoglobin level at Screening requiring transfusion. The subject may be rescreened when the condition is considered stable 3. Untreated carcinoma of the TWA or history of carcinoma within 5 years prior to Screening, except adequately treated cutaneous squamous or basal cell carcinoma. 4. Life expectancy less than 6 months, as assessed by the Investigator 5. Current or known history of clinically significant hepatic or renal disease, that in the opinion of the Investigator, could impact subject safety or study participation. 6. Treatment with any systemic immunomodulators, immunosuppressants or cytotoxic chemotherapy within 2 months prior to the Baseline visit. 7. Known hypersensitivity to oligonucleotide treatment or any of the excipients of the IMP (see Section 3.1 in the IB) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Assessment of adverse events/serious adverse events - Assessment of exon 73 exclusion in COL7A1 mRNA, measured by droplet digital polymerase chain reaction (ddPCR™)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- AEs are assessed throughout the study - Exon skip is assessed after 2 or 4 weeks of treatment, preferably prior to closure of the selected wound area |
|
E.5.2 | Secondary end point(s) |
- Wound size (surface area) - Wound severity as assessed by Physician Subjective Assessment of Severity (PSAS) and Physician Subjective Assessment of Change (PSAC) - Wound status as assessed by Short Wound Specific Questionnaire (SWSQ) - Status of wound closure - Onset of (re)blistering of a healed wound - Serum levels of QR-313 - Presence of collagen type VII protein expression, measured by indirect immunofluorescence (IIF) microscopy - Presence of anchoring fibrils measured by transmission electron microscopy (TEM) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- weekly images are taken throughout the study for the purpose of the wound healing and skin strength parameters - serum level of QR-313 is measured after 2 weeks of treatment and EOS - collagen type VII protein expression at 8 weeks after last dose of IMP (EOS) - anchoring fibrils measured at 8 weeks after last dose of IMP (EOS)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Czech Republic |
France |
Germany |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |